INTERNATIONAL | U.S.
Careers
Contact Us
About us
Products
Events, News & Press
Visit this section
Visit this section
Explore our news

Veryan Design Intelligence:
imagination + intuition + innovation

Our Vision

'We exist to improve patient care and quality of life through imagination, intuition and innovation'

 

Our Purpose

‘Transforming lives through design intelligence’

BioMimics-3D® Vascular Stent System

The BioMimics-3D Vascular Stent System has a unique 3D helical geometry which imparts a gentle helical shape to the stented artery.

Read more
MIMICS-2 3-year data released

Professor Thomas Zeller PI of the MIMICS-2 IDE study has announced that the freedom from CDTLR at 3 years for the BioMimics 3D stent was 81%, which is comparable to the outcomes for DCB, DES and Supera, despite treating more challenging lesions and without the need for lesion preparation.

Read more
Veryan & Otsuka

Veryan was founded in 2005 as the result of a technology spin out from Imperial College, London.

Read more

The Latest from Veryan

News, updates and press releases

Veryan Medical announces multimillion-euro investment in Galway operation

6th April 2021 - Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further expansion and diversification of Veryan’s product portfolio beyond the BioMimics 3D Swirling Flow stent.

Read more
First patient enrolment in MIMICS 3D USA

16th Dec 2020 - Veryan Medical (Horsham, UK) is delighted to announce that the first patient was enrolled today in the MIMICS-3D USA study by John H. Rundback MD at NJ Endovascular & Amputation Prevention, NJ.

Read more
First BioMimics 3D US Implant

2nd September 2020 - Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up, MIMICS-2.

Read more

Get in touch

Find contact details and send us a message.

Contact us